CLVT

LONDON, Nov. 4, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap") set forth in the Offer to Purchase.

Clarivate NYSE: CLVT said it completed the sale of its Life Sciences & Healthcare segment ahead of schedule during the third quarter, leaving the company focused on its Academia & Government and Intellectual Property businesses. Management said the reshaped company has approximately $2 billion in revenue, with recurring organic revenue representing 93% of the total.

Clarivate Plc (CLVT) Q3 2026 Earnings Call Transcript

Clarivate PLC (CLVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.18 per share a year ago.

— Improved recurring organic revenue growth driven by portfolio transformation  and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare segment — LONDON, Nov. 3, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2026. Executive Commentary Matti Shem Tov, Chief Executive Officer: "Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment.

LONDON, Nov. 2, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced it will bring trusted CompuMark trademark data and insights into Microsoft Copilot through IPOne, enabling intellectual property (IP) professionals to put authoritative trademark intelligence to work directly within AI-powered workflows. As AI changes how IP professionals research, analyze and make decisions, the quality of the data behind those decisions matters more than ever.

More than 100 institutions across 25 countries and regions are using the AI-native research intelligence platform. LONDON, Oct. 22, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that more than 100 institutions across 25 countries and regions have adopted Web of Science Research Intelligence, highlighting growing global customer demand since the platform launched in May 2026.

WASHINGTON--(BUSINESS WIRE)--Sterne, Kessler, Goldstein & Fox (Sterne Kessler), a market leading intellectual property (IP) law firm, today announced a co-development partnership with Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, to develop AI-enhanced patent workflow solutions. This partnership brings together Sterne Kessler's practitioner-built technology and deep patent practice expertise with Clarivate's leading IP data and software. Together, the.

Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments Proceeds strengthen balance sheet and enhance financial flexibility LONDON, Oct. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced the successful completion of the sale of its Life Sciences & Healthcare segment to Altaris, LLC ("Altaris"), advancing Clarivate's transformation and simplifying its portfolio. The transaction for $600 million was previously announced on July 6, 2026.

LONDON, Sept. 24, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration and final results of its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding 3.875% Senior Secured Notes due 2028 (the "Notes") for aggregate principal amount of up to $75,000,000 (the "Maximum Amount"), upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase") and any related documents (collectively with the Offer to Purchase, the "Tender Offer Documents").